Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1 3Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1

Interventions

Specimen Handling 98Biopsy 69Magnetic Resonance Spectroscopy 63pembrolizumab 46Cyclophosphamide 43fludarabine 38Carboplatin 22venetoclax 19Nivolumab 18Cetuximab 18Bevacizumab 17Radiotherapy 16fludarabine phosphate 15Cisplatin 15X-Rays 14Ipilimumab 13Fluorouracil 13Cytarabine 13Temozolomide 12Leucovorin 12Irinotecan 12atezolizumab 11Radiation 11Paclitaxel 11Azacitidine 11durvalumab 10Oxaliplatin 10Injections 10Gemcitabine 10Dexamethasone 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × niraparib × 30 days × Clear all
NCT04502602 2026-05-11

iNNOVATE

Virginia Commonwealth University

Phase 1 Active not recruiting
18 enrolled
Gynecologic

Ovarian Neoplasms

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
136 enrolled
Genitourinary

Prostatic Neoplasms

NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

EMD Serono

Phase 1 Active not recruiting
161 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡